INC424B
Drug
Novartis Pharma AG
Total Payments
$326,933
Transactions
78
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $297,421 | 40 | 1 |
| 2017 | $29,512 | 38 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $326,933 | 78 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CINC424B2301 | Novartis Pharma AG | $326,933 | 1 |
Top Doctors Receiving Payments for INC424B
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $325,808 | 72 |
| , MD | Diagnostic Radiology | New York, NY | $1,125 | 6 |
Ad
Manufacturing Companies
- Novartis Pharma AG $326,933
Product Information
- Type Drug
- Total Payments $326,933
- Total Doctors 1
- Transactions 78
About INC424B
INC424B is a drug associated with $326,933 in payments to 1 healthcare providers, recorded across 78 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharma AG.
Payment data is available from 2017 to 2018. In 2018, $297,421 was paid across 40 transactions to 1 doctors.
The most common payment nature for INC424B is "Unspecified" ($326,933, 100.0% of total).
INC424B is associated with 1 research study, including "CINC424B2301" ($326,933).